Henry Schein (NASDAQ:HSIC) Cut to “Buy” at Wall Street Zen

Henry Schein (NASDAQ:HSIC) was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

Several other research analysts have also weighed in on the stock. Barrington Research set a $97.00 target price on shares of Henry Schein and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. Mizuho lifted their price target on shares of Henry Schein from $81.00 to $88.00 and gave the company a “neutral” rating in a research report on Wednesday, February 25th. Barclays initiated coverage on Henry Schein in a research note on Monday, December 8th. They set an “overweight” rating and a $86.00 price target on the stock. Robert W. Baird set a $100.00 price target on Henry Schein and gave the stock an “outperform” rating in a report on Monday, February 23rd. Finally, UBS Group lifted their price objective on Henry Schein from $79.00 to $87.00 and gave the stock a “neutral” rating in a report on Wednesday, February 25th. Six analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Henry Schein has a consensus rating of “Hold” and a consensus target price of $85.58.

Henry Schein Price Performance

Henry Schein stock opened at $75.57 on Friday. The company has a market cap of $8.67 billion, a P/E ratio of 23.11, a price-to-earnings-growth ratio of 2.22 and a beta of 0.88. Henry Schein has a one year low of $60.56 and a one year high of $89.29. The business has a fifty day moving average of $78.21 and a two-hundred day moving average of $72.83. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.76 and a current ratio of 1.38.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.30 by $0.04. The business had revenue of $3.44 billion for the quarter, compared to analysts’ expectations of $3.34 billion. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The business’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same period in the prior year, the company posted $1.19 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, analysts predict that Henry Schein will post 4.74 earnings per share for the current fiscal year.

Insider Buying and Selling at Henry Schein

In other news, Director Philip A. Laskawy sold 2,844 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $80.36, for a total transaction of $228,543.84. Following the completion of the transaction, the director directly owned 21,961 shares of the company’s stock, valued at $1,764,785.96. This trade represents a 11.47% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Mark E. Mlotek sold 5,925 shares of Henry Schein stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $80.80, for a total value of $478,740.00. Following the transaction, the executive vice president owned 80,554 shares of the company’s stock, valued at $6,508,763.20. This represents a 6.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 104,556 shares of company stock worth $8,476,351. 1.08% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Henry Schein

Large investors have recently bought and sold shares of the stock. Westwood Holdings Group Inc. purchased a new position in Henry Schein in the 2nd quarter valued at about $20,631,000. AlphaQuest LLC grew its holdings in shares of Henry Schein by 91.8% during the third quarter. AlphaQuest LLC now owns 20,861 shares of the company’s stock worth $1,385,000 after buying an additional 9,987 shares in the last quarter. Berger Financial Group Inc purchased a new stake in shares of Henry Schein during the third quarter worth about $2,981,000. Marshall Wace LLP raised its position in shares of Henry Schein by 230.7% in the second quarter. Marshall Wace LLP now owns 310,166 shares of the company’s stock valued at $22,658,000 after buying an additional 216,389 shares during the last quarter. Finally, SVB Wealth LLC acquired a new position in shares of Henry Schein in the second quarter valued at approximately $1,415,000. Institutional investors and hedge funds own 96.62% of the company’s stock.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.